



CONTACT:
Investor Relations
David Isserman
877-895-5647
IR@nutrapharma.com

NUTRA PHARMA ANNOUNCES RECEPTOPHARM TO PRESENT AT THE INTERNATIONAL CONFERENCE ON NEUROTOXINS

Boca Raton, FL. – November 28, 2006 - Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS) has announced today that its holding, ReceptoPharm, has been invited to present its recent analgesic research on RPI-78M at the International Conference on Neurotoxins (ICoN) in Hollywood, Florida.

“It is exciting to be able to present the results of our research at the 2006 ICoN meeting,” commented Dr. Paul Reid, CEO of ReceptoPharm, Inc. “We are planning to discuss our research and findings on the relief of pain using our lead drug candidate, RPI-78M,” he added.

In September 2006, Neuroscience Bulletin published the positive results of a ReceptoPharm study on the use of RPI-78M for the relief of pain. The study confirms that RPI-78M has analgesic activity and supports some of the clinical reports of pain relief in subjects with herpes infections and rheumatoid arthritis.

“The purpose of this study was to examine the pain relieving effects of RPI-78M in laboratory rats and mice,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “The prolonged analgesic activity suggests that RPI-78M could be very useful in combination with other analgesic agents currently in use,” he concluded.

ReceptoPharm recently announced their approval by the British Medicines and Healthcare products Regulatory Agency to begin Phase IIB human trials with RPI-78M for the treatment of AMN (Adrenomyeloneuropathy).

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.NutraPharma.com>
<http://www.ReceptoPharm.com>

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The presentation at the ICoN meeting should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

###